Cargando…

Review of the COVID-19 Risk in Multiple Sclerosis

The ongoing pandemic of the novel coronavirus of 2019 (COVID-19) has resulted in over 1 million deaths, primarily affecting older patients with chronic ailments. Multiple sclerosis (MS) patients have been deemed particularly vulnerable given their high rates of disability and increased susceptibilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhry, Farhan, Jageka, Cristina, Levy, Phillip D., Cerghet, Mirela, Lisak, Robert P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098748/ https://www.ncbi.nlm.nih.gov/pubmed/33959727 http://dx.doi.org/10.33696/immunology.3.080

Ejemplares similares

COVID-19 in multiple sclerosis patients and risk factors for severe infection
por: Chaudhry, Farhan, et al.
Publicado: (2020)

Melanocortins, Melanocortin Receptors and Multiple Sclerosis
por: Lisak, Robert P., et al.
Publicado: (2017)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Perfusion and Diffusion Abnormalities of Multiple Sclerosis Lesions and Relevance of Classified Lesions to Disease Status
por: Li, Lian, et al.
Publicado: (2014)

MULTIPLE SCLEROSIS OR FABRY DISEASE – PROS AND CONS
por: Zavoreo, Iris, et al.
Publicado: (2018)

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis
por: Arnason, Barry G, et al.
Publicado: (2013)

Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target
por: Zahoor, Insha, et al.
Publicado: (2022)

Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism
por: Fitzgerald, Kathryn C., et al.
Publicado: (2021)

Resting state fMRI connectivity analysis as a tool for detection of abnormalities in five different cognitive networks of the brain in Multiple Sclerosis patients
por: Nejad-Davarani, Siamak P., et al.
Publicado: (2016)

Manipulation of ACE2 expression in COVID-19
por: Chaudhry, Farhan, et al.
Publicado: (2020)

3285 Toxicity of Released B Cell Products in Multiple Sclerosis: Effects on Neurons and Oligodendrocytes
por: Zuroff, Leah, et al.
Publicado: (2019)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings
por: Goldschmidt, Carolyn, et al.
Publicado: (2022)

COVID‐19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis
por: Zhang, Hanyu, et al.
Publicado: (2022)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Intussusception in the Setting of an Ulcerative Colitis Flare
por: Abed, Varag, et al.
Publicado: (2022)

Myasthenic crisis in COVID-19
por: Delly, Fadi, et al.
Publicado: (2020)

Is multiple sclerosis a risk factor for infections?
por: Lechner-Scott, Jeannette, et al.
Publicado: (2020)

Era of COVID-19 in Multiple Sclerosis Care
por: Krett, Jonathan D., et al.
Publicado: (2023)

MOG Antibody–Associated Disease and Thymic Hyperplasia: From the National Multiple Sclerosis Society Case Conference Proceedings
por: Hurtubise, Brigitte, et al.
Publicado: (2022)

Multiple sclerosis patients and COVID-19
por: Mado, Hubert, et al.
Publicado: (2021)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Reply from the authors: Myasthenic crises in COVID-19
por: Syed, Maryam J., et al.
Publicado: (2020)

Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

Neuromyelitis Optica in a Young Woman With Tuberous Sclerosis: Is There an Association?
por: Elkhooly, Mahmoud, et al.
Publicado: (2022)

The psychological impact of the COVID-19 pandemic on people with multiple sclerosis
por: Vacaras, Vitalie, et al.
Publicado: (2023)

Multiple sclerosis management during the COVID-19 pandemic
por: Moss, Brandon P, et al.
Publicado: (2020)

Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis
por: Etemadifar, M., et al.
Publicado: (2022)

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021)

Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
por: Coyle, Patricia K., et al.
Publicado: (2021)

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina
por: Cristiano, E, et al.
Publicado: (2020)

Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
por: Immovilli, Paolo, et al.
Publicado: (2022)

Awareness of COVID-19 Symptoms, Risk Factors, and Vaccinations in Patients with Multiple Sclerosis
por: Krzystanek, Ewa, et al.
Publicado: (2022)

Encephalitis and Myelitis in a Young Woman: Overlap Syndrome, Thyroiditis, and Occult Tumor From the National Multiple Sclerosis Society Case Conference Proceedings
por: Zarghami Esfanhani, Neda, et al.
Publicado: (2021)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Multiple sclerosis and COVID‐19: The Swedish experience
por: Landtblom, Anne‐Marie, et al.
Publicado: (2021)

Response of the multiple sclerosis community to COVID-19
por: Ciccarelli, Olga, et al.
Publicado: (2020)

Characteristics of COVID-19 in patients with multiple sclerosis
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5versc97afut9bj85ur02loo2v